News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Staff Note Financial Ties in Zimmer Holdings Inc. Spine Study
November 3, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. reviewers have raised the possibility of bias in the evaluation of a spine device made by Zimmer Holdings Inc (ZMH.N), saying a majority of patients in a study were treated by researchers with a financial interest in the company.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
FDA
FDA’s latest rare disease framework seeks to prioritize consistency in flexibility
October 15, 2026
·
4 min read
·
Michael Gibney
IN PARTNERSHIP WITH ROSE BIOSOLUTIONS
Successful CDMO partnerships hinge on honest—and sometimes critical—support
October 12, 2026
·
5 min read
·
Jennifer C. Smith-Parker
Drug Development
Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold
October 8, 2026
·
2 min read
·
Gabrielle Masson
Opinion
FDA must ensure American patients can access new and experimental drugs
October 5, 2026
·
7 min read
·
Houman David Hemmati